Skip to main content

Table 1 Demographic and clinical history of patients that qualified for the survival analysis

From: Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide

Demographics Patients evaluable at baseline Patients evaluable at 12-week treatment follow-up
(N = 80) (N = 62)
  Median (range)
Age 71 (54–84) 71 (54–84)
PSA at diagnosis 46 (3.7–4625) 46 (3.7–1018)
Primary treatment N (%)
Radiation therapy 22 (28) 19 (30)
Radical prostatectomy 13 (16) 9 (15)
Prior systemic treatment  
Prior ADT 80 (100) 62 (100)
Prior chemo 64 (80) 47 (75)
Covariates Median (range)
PSA (ng/mL) 157.5 (1.1–5460) 149 (1.1–5460)
ALP (U/L) 124.3 (41.2–1058)
HgB (mmol/L) 7.5 (5.2–10.0)
BSI 2.7 (0.01–21.11) 2.6 (0.01–21.11)
  N (%)
Deaths 56 (70) 40 (65)